Evidence map›Paper›PMID 41816293›Full record

ArticleiScience2026

NPC2 suppresses osteolytic metastasis in lung adenocarcinoma via the AKT/mTOR pathway and tumor-osteoclast crosstalk.

Si Zhou, Ning Li, Ruping Li, Ying Ding, Yichen Zhu, Yan Pan, Yan Liu, Yingying Zhang, Hui Yang, Qiming Wang

Abstract read
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Si ZhouDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Ning LiDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Ruping LiDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Ying DingDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Yichen ZhuInstitute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou 451162, China.
Yan PanInstitute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou 451162, China.
Yan LiuInstitute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou 451162, China.
Yingying ZhangDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Hui YangDepartment of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Qiming WangInstitute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou 451162, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lysosomal-related protein NPC2 affects the occurrence and development of tumors in terms of stemness, gene mutational burden, and microsatellite instability of tumor cells. Here, combining with our previous scRNA-seq data, we identified the protective role of NPC2 in bone metastasis of lung adenocarcinoma (LUAD). Bone metastases exhibited lower NPC2 expression compared to primary tumors, and low NPC2 expression was associated with poorer LUAD patient survival. NPC2 knockdown LUAD cells exhibited enhanced migration capability, and their supernatant accelerated the osteoclast differentiation and maturation.

Indexed as

Biological sciencesCancer

Identifiers

PMID41816293
PMCPMC12972735

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.